Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases.

Salmon, Michael; Luttmann, Mark A; Foley, James J; Buckley, Peter T; Schmidt, Dulcie B; Burman, Miriam; Webb, Edward F; DeHaas, Christopher J; Kotzer, Charles J; Barrett, Victoria J; Slack, Robert J; Sarau, Henry M; Palovich, Michael R; Lainé, Dramane I; Hay, Douglas W P; Rumsey, William L

Salmon, Michael; Luttmann, Mark A; Foley, James J; Buckley, Peter T; Schmidt, Dulcie B; Burman, Miriam; Webb, Edward F; DeHaas, Christopher J; Kotzer, Charles J; Barrett, Victoria J; Slack, Robert J; Sarau, Henry M; Palovich, Michael R; Lainé, Dramane I; Hay, Douglas W P; Rumsey, William L.

Affiliation

Salmon M; GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA.

J Pharmacol Exp Ther ; 345(2): 260-70, 2013 May.

Article in En | MEDLINE | ID: mdl-23435542

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinuclidines / Muscarinic Antagonists / Lung Diseases Type of study: Prognostic_studies Aspects: Patient_preference Limits: Animals Language: En Journal: J Pharmacol Exp Ther Year: 2013 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google